SHAPE and ASPC press USPSTF to update preventive care review methods

SHAPE and the American Society for Preventive Cardiology are asking the U.S. Preventive Services Task Force to move faster on emerging evidence and give earlier-detection tools more room in prevention guidance. The letter argues that imaging, biomarkers and other technologies are reshaping how clinicians find disease before symptoms appear, and it urges clearer research priorities when evidence is incomplete.

Why it matters: - Preventive-care guidance shapes what clinicians screen for, what insurers cover and which patients get earlier treatment. - The letter argues that current review methods may move too slowly for imaging, biomarkers and artificial intelligence tools that can detect subclinical disease before symptoms begin. - Earlier detection could change risk assessment, patient-clinician conversations and when preventive interventions start.

What happened: - The Society for Heart Attack Prevention and Eradication and the American Society for Preventive Cardiology sent an open letter on Sept. 23 to newly appointed members of the U.S. Preventive Services Task Force. - The letter was addressed to Task Force Chair Seth J. Corey, MD, MPH, and members of the USPSTF. - Copies went to Robert F. Kennedy, Jr., Secretary of Health and Human Services; Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services; and Roger D. Klein, MD, JD, director of the Agency for Healthcare Research and Quality. - SHAPE and ASPC signed the letter with a broad coalition of physicians, scientists, imaging experts, public health leaders and health policy specialists.

The details: - The coalition asks the USPSTF to incorporate emerging evidence more continuously as preventive science evolves. - The letter urges more scientific discussion about when detecting disease itself, not only measuring risk factors, should influence preventive recommendations. - The group wants earlier engagement with specialty experts and scientific organizations working in fast-moving areas of prevention. - The letter says randomized clinical trials remain critically important. - The letter also says large prospective cohorts, registries, real-world evidence, validated modeling and other methods may complement randomized trials when long-term trial data are not yet available. - The coalition asks the USPSTF to be more explicit about evidence gaps and to define the research needed when evidence is judged insufficient. - The letter cites cardiovascular disease as a key example of the shift from risk-factor-based prevention to earlier detection of disease already present but not yet symptomatic. - The full letter is available here.

Between the lines: - The letter is not asking the USPSTF to lower its standards. - It is pushing the Task Force to update how it weighs evidence so newer technologies are not left out simply because long-term randomized outcomes are still emerging. - That could matter for fields where clinical practice is moving faster than traditional guideline timelines. - The signatories span preventive cardiology, imaging, oncology, lung cancer screening, endocrinology, epidemiology, health economics, artificial intelligence, population health and clinical trials, which signals a broader prevention debate beyond heart disease alone.

What's next: - The coalition says it welcomes the chance to contribute evidence from cardiovascular prevention, imaging and early disease detection. - Future USPSTF review methods may face pressure to define when complementary evidence is strong enough to inform recommendations. - If the Task Force revises its approach, future prevention guidance could place more weight on subclinical disease detection alongside traditional risk-factor screening.

The bottom line: - SHAPE and ASPC want the USPSTF to keep its evidence bar high while moving faster on tools that can find disease earlier.